We are live on ! Find out more
IMUX icon

Immunic
IMUX

43 hedge funds and large institutions have $1.16M invested in Immunic in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.04% → 0.03% (-0%)

4% less capital invested

Capital invested by funds: $1.22M → $1.16M (-$53.6K)

9% less funds holding

Funds holding: 47 → 43 (-4)

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
43
Holders Change
-4
Holders Change %
-8.51%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
16
Closed
8
Calls
$49K
Puts
–
Net Calls
+$49K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$77K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$17.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$15.1K
4
SG Americas Securities
SG Americas Securities
New York
+$13.4K
5
Goldman Sachs
Goldman Sachs
New York
+$8.7K

Top Sellers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
-$117K
2
VF
Virtu Financial
New York
-$58K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$26.4K
4
Two Sigma Investments
Two Sigma Investments
New York
-$25.6K
5
BlackRock
BlackRock
New York
-$16.6K

IMUX Hedge Fund Activity: Q1 2019 in Review

43 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2019, worth a combined $1.16M — down 4.4% from $1.22M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of IMUX and 4 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 11 added.

The largest buyer was GSA Capital Partners, adding an estimated $77K. The largest seller was AQR Capital Management, cutting an estimated $117K.

  • 43 institutional investors held Immunic (IMUX) as of Q1 2019, down from 47 in Q4 2018.
  • Funds reported $1.16M of Immunic stock for Q1 2019, down 4.4% quarter-over-quarter.
  • 4 funds opened new Immunic positions in Q1 2019 and 8 closed out, a net change of -4 holders.
  • The largest Immunic buyer in Q1 2019 was GSA Capital Partners, an estimated $77K added.
  • The largest Immunic seller in Q1 2019 was AQR Capital Management, an estimated $117K sold.

Based on aggregated 13F filings for Q1 2019.